The U.S. has about 90 million dogs, and around 80% visit a vet annually. This suggests a market of roughly 72 million dogs that could be diagnosed and treated. Prices for the drug vary by weight, but vets typically charge over $80 per dose, with Zoetis Inc (NYSE:ZTS) earning about $40 per treated dog each month, or $480 annually. Andvari Associates stated the following regarding Zoetis Inc. (NYSE:ZTS) in its Q2 2024 investor letter: "Zoetis Inc. (NYSE:ZTS) was spun out of Pfizer in 2013 and is the largest company serving the animal health market. They make medicines, vaccines, diagnostics, devices, and technology solutions for their pet owners and veterinarians. Their revenues are split 65% for pet care and 35% for livestock. Overall, Zoetis Inc (NYSE:ZTS) ranks 4th on Insider Monkey's list titled Jim Cramer Stock Portfolio for Q4: Top 11 Stocks to Buy and Sell.